Machine Learning Applications In Early Disease Prediction

Abstract

Early disease prediction seeks to identify individuals who are likely to develop a condition, deteriorate, or experience a serious complication before conventional diagnosis becomes possible. Machine learning has widened this field by enabling computers to detect complex patterns across electronic health records, medical images, laboratory results, genomic profiles, wearable sensors, and patient reported data. This review examines the principal applications, theoretical foundations, evidence base, research methods, clinical value, and limitations of machine learning in early disease prediction. It adopts an integrative review design and synthesizes peer reviewed research and major reporting, ethical, and regulatory guidance. The literature indicates that machine learning can improve risk stratification for cardiovascular disease, diabetes, cancer, sepsis, kidney disease, neurological disorders, and other conditions, especially when longitudinal and multimodal data are available. However, strong performance in a development dataset does not guarantee clinical benefit. Bias, data leakage, poor calibration, limited external validation, changing clinical environments, weak interpretability, privacy risks, and alert fatigue can reduce effectiveness or produce harm. The article therefore argues that machine learning should be treated as a clinical prediction intervention rather than merely a technical model. Its value depends on representative data, transparent reporting, prospective evaluation, human oversight, equitable deployment, and continuous monitoring. Future work should prioritize clinically meaningful outcomes, cross site validation, privacy preserving collaboration, explainable interfaces, and implementation research that measures effects on decisions, workflows, costs, and patient health.